Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Repeat Topical Botulinum Toxin Type A for Crow's Feet
NCT01818076Phase 3Terminated
- Sponsor
- Revance Therapeutics
- Start
- Feb 2013
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daxibotulinumtoxinA in periorbital wrinkles, sponsored by Revance Therapeutics. Started Feb 2013; status: terminated.
02
Drugs
daxibotulinumtoxinA
03
Conditions
periorbital wrinkles
Beyond the preview
Go deeper on NCT01818076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818076.